Primal Herbs Recalls Volume Supplement Over Undeclared Sildenafil

Primal Supplements Group, a New Mexico-based dietary supplement manufacturer, has initiated a nationwide voluntary recall of its Primal Herbs Volume product following laboratory confirmation of undeclared sildenafil citrate—the active pharmaceutical ingredient found in Viagra. The recall affects all units sold between July 2 and September 19, 2025, exclusively through the company's direct-to-consumer website, primalherbs.com.

The contamination was identified through routine third-party testing, prompting immediate action from the manufacturer in coordination with FDA oversight. Consumers who purchased the 8.5-ounce containers during the affected period are being advised to discontinue use immediately and contact the company for full refunds. No adverse events have been publicly reported to date, though the FDA has emphasized that sildenafil poses significant health risks when taken without medical supervision.

Health Risks Associated With Undeclared Sildenafil

Sildenafil citrate is a prescription medication approved for treating erectile dysfunction and pulmonary arterial hypertension. Its presence in an over-the-counter supplement creates multiple safety concerns, particularly for consumers who may be unaware they are ingesting a potent pharmaceutical agent. According to FDA guidance, sildenafil can interact dangerously with nitrates commonly prescribed for heart conditions, potentially causing life-threatening drops in blood pressure.

The risks are compounded when consumers take the supplement believing it contains only natural herbal ingredients. Individuals with cardiovascular conditions, diabetes, or those taking multiple medications face elevated risks. The lack of dosage control in contaminated supplements creates additional uncertainty—consumers have no way to know how much sildenafil they are actually consuming per serving.

Key health risks include:

• Dangerous interactions with nitrate medications for heart disease
• Severe blood pressure fluctuations in individuals with cardiovascular conditions
• Unpredictable effects in people taking multiple medications
• Potential complications for individuals with diabetes or kidney disease
• Risk of priapism and other adverse effects without medical monitoring

Pattern of Contamination in Male Enhancement Supplements

This recall represents the latest incident in an ongoing challenge facing the dietary supplement industry, particularly within the male enhancement category. FDA databases show that erectile dysfunction drug ingredients—including sildenafil, tadalafil, and their analogues—are among the most frequently detected pharmaceutical contaminants in supplements marketed for sexual health.

Industry analysts note that economic incentives drive some manufacturers to adulterate products with pharmaceutical ingredients to deliver immediate, noticeable effects that consumers associate with product efficacy. This practice not only violates FDA regulations but fundamentally undermines consumer trust in the legitimate supplement industry. The contamination may occur at various points in the supply chain, from raw material sourcing to manufacturing processes that lack adequate quality controls.

The prevalence of these incidents has prompted regulatory experts to call for enhanced testing requirements and supply chain transparency. According to recent FDA enforcement data, the agency has issued warning letters to more than 70 companies in the past three years for marketing supplements containing undeclared pharmaceutical ingredients.

Regulatory Response and Industry Implications

The FDA's current regulatory framework for dietary supplements differs significantly from pharmaceutical oversight, relying heavily on post-market surveillance rather than pre-market approval. This recall underscores ongoing debates about whether the existing regulatory structure adequately protects consumers from contaminated or adulterated products.

Consumer advocacy groups have renewed calls for mandatory third-party testing and certification for supplement manufacturers, particularly those selling products with claims related to sexual health, weight loss, or athletic performance—categories with historically high contamination rates. Several industry trade associations have responded by promoting voluntary quality standards and encouraging members to implement rigorous testing protocols.

For consumers seeking to verify supplement safety, tools like PharmoniQ's Supplement Safety Checker provide evidence-based assessments of product ingredients and potential interactions. The platform analyzes supplement formulations against databases of known contaminants and provides personalized risk assessments based on individual health conditions and medications.

What This Means for Consumers

This recall serves as an important reminder that "natural" or "herbal" marketing claims do not guarantee product purity or safety. Consumers should approach supplement purchases with informed skepticism, particularly for products making claims about sexual performance, rapid weight loss, or dramatic results.

Healthcare professionals emphasize the importance of discussing all supplement use with physicians, especially for individuals with chronic health conditions or those taking prescription medications. The discovery of pharmaceutical ingredients in supplements marketed as natural alternatives represents a serious health risk that extends beyond individual product failures to systemic challenges in supplement industry oversight.

Looking ahead, this incident may accelerate regulatory discussions about enhanced testing requirements and supply chain verification for dietary supplement manufacturers. As the supplement market continues to expand—projected to exceed $230 billion globally by 2027—ensuring product integrity remains a critical challenge for regulators, manufacturers, and consumers alike.

Consumers who purchased Primal Herbs Volume during the recall period should contact the company directly at the information provided on primalherbs.com or consult with their healthcare provider about potential health implications.